Syncell
Syncell raises $15M Series A at $75M valuation
Quick Facts
Syncell: Series A Funding Round
Syncell has successfully raised $15M in Series A funding, reaching a valuation of $75M.
Company Overview
Cell therapy manufacturing platform for regenerative medicine
Funding Details
The Series A round was led by Taiwania Capital, with participation from KdT Ventures.
Company Information
- Headquarters: Taipei, Taiwan
- Founded: 2020
- Employees: 60+
- Category: Biotech
Investment
Syncell plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Taiwania Capital: Verified investor in Series A
- KdT Ventures: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
